Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FBIO - Fortress Biotech, Inc.

IEX Last Trade
2.285
0.025   1.094%

Share volume: 12,101
Last Updated: Fri 27 Dec 2024 08:29:38 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$2.26
0.03
1.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 20%
Liquidity 74%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
18.39%
1 Month
12.57%
3 Months
38.26%
6 Months
22.62%
1 Year
-41.14%
2 Year
298.07%
Key data
Stock price
$2.28
P/E Ratio 
0.00
DAY RANGE
$2.09 - $2.29
EPS 
$0.00
52 WEEK RANGE
$1.44 - $3.34
52 WEEK CHANGE
-$31.56
MARKET CAP 
46.312 M
YIELD 
N/A
SHARES OUTSTANDING 
22.814 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
1.38
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$511,546
AVERAGE 30 VOLUME 
$723,345
Company detail
CEO: Lindsay A. Rosenwald
Region: US
Website: fortressbiotech.com
Employees: 170
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also develops late stage product candidates such as intravenous Tramadol for the treatment of post-operative acute pain.

Recent news